AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9570170 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg 3 times a day plus Omeprazole 40 mg daily for 14 days followed by 20 mg daily for 14 days (Group 1)
Number of subjects: 819
Study 9570170 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg daily for 28 days (Group 2)
Number of subjects: 819
Study 9570170 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine hydrochloride 150 mg twice a day for 28 days (Group 3)
Number of subjects: 819
Study 9570170 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin plus Omeprazole (Group 1)
Number of subjects: 819
Study 7851071 — intervention group
Group type: EXPERIMENTAL
Intervention: OpSite dressings
Number of subjects: 33
Study 3049046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepin
Number of subjects: 100
Study 3049046 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 100
Study 16961011 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant conditioning with positive reinforcements of candy
Number of subjects: 20
Study 16961011 — intervention group
Group type: COMPARATOR
Intervention: Interpretive play therapy
Number of subjects: 20
Study 30246216 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) supplementation
Number of subjects: 50
Study 30246216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30268262 — intervention group
Group type: EXPERIMENTAL
Intervention: Kefir group (2 × 100 ml of kefir per day)
Number of subjects: 45
Study 30268262 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste group (toothpaste with probiotic content, brushed twice a day)
Number of subjects: 45
Study 30268262 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotic treatment)
Number of subjects: 45
Study 27046162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 1143
Study 27046162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily
Number of subjects: 1143
Study 27046162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (pooled doses)
Number of subjects: 1143
Study 27046162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1143
Study 24473502 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone plus ranolazine (1500 mg single oral dose)
Number of subjects: 121
Study 24473502 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone alone
Number of subjects: 121
Study 21538705 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly
Number of subjects: 0
Study 21538705 — intervention group
Group type: COMPARATOR
Intervention: Young controls
Number of subjects: 0
Study 21070678 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Glycemic Load (LGL) breakfast
Number of subjects: 23
Study 21070678 — intervention group
Group type: COMPARATOR
Intervention: High-Glycemic Load (HGL) breakfast
Number of subjects: 23
Study 17105777 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 35
Study 17105777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 15581647 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological attributions and perception-related factors
Number of subjects: 151
Study 15581647 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower age, male sex, CFS-like caseness, and less cognitive difficulties
Number of subjects: 151
Study 15581647 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower physical functioning scores
Number of subjects: 151
Study 11281469 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors (unemployment, anxiety, perceived inconvenience, abdominal pain, haemoglobin level, serum ferritin concentration)
Number of subjects: 226
Study 11281469 — intervention group
Group type: COMPARATOR
Intervention: Normal menstrual blood loss (<60 mL)
Number of subjects: 226
Study 9690973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole (12-24 mg/day)
Number of subjects: 0
Study 9690973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole (24 mg)
Number of subjects: 0
Study 9690973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 0
Study 9690973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8045864 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic foot contact monitor for estimating metabolic cost of locomotion (Mloco)
Number of subjects: 12
Study 8045864 — intervention group
Group type: EXPERIMENTAL
Intervention: Equation derived from six subjects: Mloco = 3.702.(Wb/tc) - 149.6 (r2 = 0.93)
Number of subjects: 12
Study 3132812 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ankle movements with weight bearing in an orthosis
Number of subjects: 51
Study 3132812 — intervention group
Group type: COMPARATOR
Intervention: Active ankle movements without weight bearing using a dorsal splint
Number of subjects: 51
Study 29576227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (duration longer than 1 year)
Number of subjects: 216
Study 29576227 — intervention group
Group type: COMPARATOR
Intervention: Control group (duration longer than 1 year)
Number of subjects: 216
Study 26957279 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoperfusion combined therapy (HD+HP)
Number of subjects: 92
Study 26957279 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (HD)
Number of subjects: 92
Study 26434090 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral joint line injection site
Number of subjects: 60
Study 26434090 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapatellar lateral injection site
Number of subjects: 60
Study 24145083 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF treatment
Number of subjects: 78
Study 24145083 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy subjects)
Number of subjects: 78
Study 24145083 — intervention group
Group type: COMPARATOR
Intervention: Control (RA patients)
Number of subjects: 78
Study 21173687 — intervention group
Group type: EXPERIMENTAL
Intervention: Metenolone enanthate (ME) 100 mg injected intramuscularly weekly for 6 weeks
Number of subjects: 26
Study 21173687 — intervention group
Group type: COMPARATOR
Intervention: Control group (CT)
Number of subjects: 26
Study 18313521 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicatheter interstitial brachytherapy (n=247) or MammoSite (n=26), receiving 32-34 Gy in 8-10 twice-daily fractions using high-dose-rate 192Ir brachytherapy.
Number of subjects: 273
Study 16550749 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-Hirudin (PEG-H)
Number of subjects: 20
Study 16550749 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 20
Study 12893716 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive
Number of subjects: 14
Study 12893716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10579155 — intervention group
Group type: EXPERIMENTAL
Intervention: New paste preparation of Gelfoam powder, Thrombostat, acetic acid, and Bacitracin ointment
Number of subjects: 0
Study 10579155 — intervention group
Group type: COMPARATOR
Intervention: Old method using small pieces of Gelfoam soaked in antibiotic solution
Number of subjects: 0
Study 8723582 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation (ABD)
Number of subjects: 0
Study 8723582 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative treatment with epoetin alfa
Number of subjects: 0
Study 8723582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of epoetin alfa and preoperative ABD
Number of subjects: 0
Study 1896663 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer analysis
Number of subjects: 20
Study 1896663 — intervention group
Group type: COMPARATOR
Intervention: Point-counting method
Number of subjects: 20
Study 7037511 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified porcine insulin
Number of subjects: 40
Study 7037511 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified porcine insulin (after removing patients with substantial changes in HbA1)
Number of subjects: 40
Study 7037511 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified porcine insulin (after removing patients with low initial insulin binding capacity)
Number of subjects: 40
Study 7037511 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine insulin (after rechallenge)
Number of subjects: 40
Study 28547866 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic Dilation (PD)
Number of subjects: 201
Study 28547866 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Heller Myotomy (LHM)
Number of subjects: 201
Study 26934504 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-days-a-week post-operative radiotherapy (p-CAIR)
Number of subjects: 84
Study 26934504 — intervention group
Group type: COMPARATOR
Intervention: Post-operative concurrent radiochemotherapy (p-RTCT)
Number of subjects: 84
Study 26934504 — intervention group
Group type: EXPERIMENTAL
Intervention: Both p-CAIR and p-RTCT
Number of subjects: 84
Study 24687640 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg nicotine patch applied during the night
Number of subjects: 66
Study 24687640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 21708892 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute rice vinegar (100 ml daily for 4 weeks)
Number of subjects: 60
Study 21708892 — intervention group
Group type: COMPARATOR
Intervention: Usual care (100 ml of water)
Number of subjects: 60
Study 19915220 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 177
Study 19915220 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apical pacing
Number of subjects: 177
Study 17907858 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized drawing with high density (CH)
Number of subjects: 116
Study 17907858 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized drawing with standard density (CS)
Number of subjects: 116
Study 17907858 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual drawing with standard prize density (MS)
Number of subjects: 116
Study 17907858 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent control group (NonC)
Number of subjects: 116
Study 14967827 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of caffeine
Number of subjects: 97
Study 14967827 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of caffeine per day for 5 days
Number of subjects: 97
Study 12565114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine-fentanyl patient-controlled epidural analgesia (PCEA)
Number of subjects: 41
Study 12565114 — intervention group
Group type: COMPARATOR
Intervention: Morphine intravenous patient-controlled analgesia (IV PCA)
Number of subjects: 41
Study 10433003 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 67
Study 10433003 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 67
Study 7586105 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg i.v.)
Number of subjects: 16
Study 7586105 — intervention group
Group type: COMPARATOR
Intervention: Midazolam infusion (0.3-0.5 mg.min-1)
Number of subjects: 16
Study 7586105 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg)
Number of subjects: 16
Study 2239119 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (bolus) followed by 0.25% (infusion)
Number of subjects: 20
Study 2239119 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% (bolus) followed by 0.125% (infusion)
Number of subjects: 20
Study 2239119 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% and 0.25%
Number of subjects: 20
Study 2239119 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% and 0.25%
Number of subjects: 20
Study 6767295 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistabron (sodium‐2‐mercaptoethane sulphonate)
Number of subjects: 27
Study 6767295 — intervention group
Group type: COMPARATOR
Intervention: Iso‐osmolar hypertonic saline
Number of subjects: 27
Study 6767295 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 27
Study 6767295 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistabron
Number of subjects: 27
Study 29891745 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (800 IU/d)
Number of subjects: 54
Study 29891745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 27702425 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education (NE) combined with agriculture intervention
Number of subjects: 921
Study 27702425 — intervention group
Group type: COMPARATOR
Intervention: Agriculture intervention only (Control)
Number of subjects: 921
Study 27702425 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education (NE)
Number of subjects: 921
Study 24637559 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sildenafil
Number of subjects: 234
Study 24637559 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose sildenafil
Number of subjects: 234
Study 24637559 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sildenafil
Number of subjects: 234
Study 24637559 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 234
Study 22798533 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 1386
Study 22798533 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 1386
Study 22798533 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen in cancer surgery
Number of subjects: 1386
Study 22798533 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen in noncancer surgery
Number of subjects: 1386
Study 20479228 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group with newly trained lexical categories for color (e.g., different shades of blue acquiring new names)
Number of subjects: 0
Study 20479228 — intervention group
Group type: COMPARATOR
Intervention: Control group with no new categories introduced, conditions matched to the experimental group
Number of subjects: 0
Study 18191684 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily spontaneous awakening trials (SATs) followed by spontaneous breathing trials (SBTs)
Number of subjects: 336
Study 18191684 — intervention group
Group type: COMPARATOR
Intervention: Sedation per usual care plus a daily SBT
Number of subjects: 336
Study 15625071 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin cream
Number of subjects: 133
Study 15625071 — intervention group
Group type: COMPARATOR
Intervention: Mupirocin cream
Number of subjects: 133
Study 12566639 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive measures (specific measures not detailed)
Number of subjects: 1165
Study 12566639 — intervention group
Group type: EXPERIMENTAL
Intervention: Increment analysis
Number of subjects: 1165
Study 12566639 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence density analysis
Number of subjects: 1165
Study 10825329 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES) at 10 mA
Number of subjects: 80
Study 10825329 — intervention group
Group type: COMPARATOR
Intervention: Cold, pinprick, and touch sensory block
Number of subjects: 80
Study 9003134 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontist-delivered tobacco-use prevention program
Number of subjects: 15464
Study 9003134 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15464
Study 1544196 — intervention group
Group type: COMPARATOR
Intervention: 50% oxygen
Number of subjects: 20
Study 1544196 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 20
Study 6379305 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent aortic cross‐clamping at 32 degrees C
Number of subjects: 72
Study 6379305 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent aortic cross‐clamping at 25 degrees C
Number of subjects: 72
Study 6379305 — intervention group
Group type: COMPARATOR
Intervention: St. Thomas' Hospital cardioplegia
Number of subjects: 72
Study 3093773 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral intravenous dextrose infusion
Number of subjects: 25
Study 3093773 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral intravenous amino acid infusion
Number of subjects: 25
Study 3093773 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 25
Study 31712981 — intervention group
Group type: COMPARATOR
Intervention: Conventional‐F toothpaste (1,450 μg F/g)
Number of subjects: 12
Study 31712981 — intervention group
Group type: COMPARATOR
Intervention: Conventional‐F + arginine/CaCO3 (1,450 μg F/g + 1.5% arginine‐CaCO3)
Number of subjects: 12
Study 31712981 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐F toothpaste (5,000 μg F/g)
Number of subjects: 12
Study 31712981 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐F + fTCP toothpaste (5,000 μg F/g)
Number of subjects: 12
Study 29199116 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 75
Study 29199116 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 75
Study 26892128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin (E/S)
Number of subjects: 1054
Study 26892128 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (ATV)
Number of subjects: 1054
Study 26892128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin + Atorvastatin (E/S + ATV)
Number of subjects: 1054
Study 23276524 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (pharmacological + psychoeducational and cognitive-behavioral therapy)
Number of subjects: 40
Study 23276524 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard pharmacological treatment)
Number of subjects: 40
Study 23276524 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (combined treatment)
Number of subjects: 40
Study 22776535 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mJ/MTZ with high MTZ density (up to 2,625 MTZ/cm²)
Number of subjects: 11
Study 22776535 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mJ/MTZ with lower MTZ density (up to 230 MTZ/cm²)
Number of subjects: 11
Study 19709693 — intervention group
Group type: COMPARATOR
Intervention: Diet (reduced total fat, saturated fat, and cholesterol intake)
Number of subjects: 274
Study 19709693 — intervention group
Group type: COMPARATOR
Intervention: Diet + PA
Number of subjects: 274
Study 19709693 — intervention group
Group type: COMPARATOR
Intervention: Diet or Diet + PA
Number of subjects: 274
Study 19709693 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 274
Study 18313273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 107
Study 18313273 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 107
Study 18313273 — intervention group
Group type: EXPERIMENTAL
Intervention: AUIC > or = 250
Number of subjects: 107
Study 18313273 — intervention group
Group type: COMPARATOR
Intervention: AUIC < 250
Number of subjects: 107
Study 18313273 — intervention group
Group type: EXPERIMENTAL
Intervention: T > MIC of 100%
Number of subjects: 107
Study 18313273 — intervention group
Group type: COMPARATOR
Intervention: T > MIC of <100%
Number of subjects: 107
Study 15967639 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 0
Study 15967639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12663559 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1274
Study 12663559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1274
Study 10636205 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors
Number of subjects: 3154
Study 8831325 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) 0.3 microgram/kg
Number of subjects: 30
Study 8831325 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 30
Study 8831325 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 6%
Number of subjects: 30
Study 1426322 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter embolization of the left testicular vein (Group 2)
Number of subjects: 88
Study 1426322 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 88
Study 1426322 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (Group 1)
Number of subjects: 88
Study 4044462 — intervention group
Group type: EXPERIMENTAL
Intervention: Latamoxef (1 g)
Number of subjects: 120
Study 4044462 — intervention group
Group type: COMPARATOR
Intervention: Cephazolin (1 g) and Metronidazole (500 mg)
Number of subjects: 120
Study 30664407 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional-Analytic Psychotherapy and Acceptance and Commitment Therapy (FACT)
Number of subjects: 43
Study 30664407 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 43
Study 29490096 — intervention group
Group type: EXPERIMENTAL
Intervention: AA-MFs
Number of subjects: 25
Study 29490096 — intervention group
Group type: COMPARATOR
Intervention: GMP-MFs
Number of subjects: 25
Study 27216710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sources of information about HPV vaccine (e.g., doctor or medical professional, television)
Number of subjects: 360
Study 27216710 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental attitudes about HPV vaccine
Number of subjects: 360
Study 27216710 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine uptake
Number of subjects: 360
Study 24530350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing educational intervention sessions of three hours on two days a week for three months
Number of subjects: 32
Study 24530350 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 21366734 — intervention group
Group type: EXPERIMENTAL
Intervention: First surveillance test attendance
Number of subjects: 2166
Study 21366734 — intervention group
Group type: EXPERIMENTAL
Intervention: First surveillance test late attendance
Number of subjects: 2166
Study 21366734 — intervention group
Group type: EXPERIMENTAL
Intervention: Second surveillance test non-attendance
Number of subjects: 2166